80 news items
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
CKPT
5 Jun 24
"that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
CKPT
4 Jun 24
cSCC who are not candidates for curative surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)
CKPT
3 Jun 24
, cosibelimab. Specifically, the Company stated that the FDA had issued a complete response letter which "cites findings that arose during a multi
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
CKPT
3 Jun 24
] has issued a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
CKPT
3 Jun 24
a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who
jof 19xe9p4j4bh5t731ibbzxrpgv3ryj
CKPT
3 Jun 24
, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients
l9my5dr2mcyhr7h7iadhfu5665d7z8nx
CKPT
2 Jun 24
or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment
hj5fa1vvi1c1xss0 8xuszf1u2v142dak5zi8bfrbdh2ncgighudel4e3
CKPT
31 May 24
surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab
t7l xa6jy2x
CKPT
31 May 24
, the Company stated that the FDA had issued a complete response letter which "cites findings that arose during a multi-sponsor inspection of Checkpoint's
su4nxa2xd3gvhdrmsip8bk9l0n2petyahumztv
CKPT
31 May 24
. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab [BLA
yohkqdky ker0
CKPT
30 May 24
cSCC who are not candidates for curative surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response
lzncb2l5ujdi556cqdljjlrlveb t1i1b8olemligps8b2620qkfs
CKPT
30 May 24
of this promotional communication, and Corey Holzer is the attorney responsible for its content. CONTACT:Corey Holzer, Esq
2n0 czvazbf4ocafrk
CKPT
30 May 24
surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab
tubb7g
CKPT
29 May 24
or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment
sjh12k5f9g okc5ccbwmpbpcm2yiei
CKPT
28 May 24
"that the [FDA] has issued a complete response letter (‘CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced
basf319ymuk7591lr5b 8p12g5rh90j7zuno
CKPT
27 May 24
a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who
04i2vdlz0gwy67dwf30g4spe0cvb3f4btwjk3b2y1knnn3bwqt5j9
CKPT
24 May 24
. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab [BLA
xtdskxvlojuwu9d0l1hf6w8zhr me53rftr8yvpo8nlx864yaer6
CKPT
22 May 24
of this promotional communication, and Corey Holzer is the attorney responsible for its content. CONTACT:Corey Holzer, Esq
qpe396t3o0mjsefrxf0j5mkoh0vx 7s9
CKPT
22 May 24
surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab
favhimh0tf24z698pz24xcns4dsauebog8rzni3m29bpa74nhbtr
CKPT
22 May 24
response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who are not candidates